Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
BP-13656 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
BP-13656: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
AK-OTOF Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
AK-OTOF: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Pomaglumetad methionil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Pomaglumetad methionil: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market.
8 min read
Pramipexole/Ondansetron Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Pramipexole/Ondansetron: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market.
8 min read
Autologous muscle precursor cells(MUVON Therapeutics AG) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Autologous muscle precursor cells(MUVON Therapeutics AG): Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development.
8 min read
Tipelukast Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Tipelukast: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
SNP-318 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
SNP-318: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
RSY-248 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
RSY-248: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Methotrexate Liposomal Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Methotrexate Liposomal: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market.
8 min read
TUL12101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
TUL12101: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
CVP-002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
CVP-002: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Oxy-Retic Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Oxy-Retic: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.